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Nef functions in BLT mice to enhance HIV-1
replication and deplete CD4+CD8+ thymocytes
Wei Zou1, Paul W Denton1, Richard L Watkins1, John F Krisko1, Tomonori Nochi1,
John L Foster1 and J Victor Garcia1,2*

Abstract
Background: The outcome of untreated HIV-1 infection is progression to AIDS and death in nearly all cases. Some
important exceptions are the small number of patients infected with HIV-1 deleted for the accessory gene, nef. With
these infections, disease progression is entirely suppressed or greatly delayed. Whether Nef is critical for high levels of
replication or is directly cytotoxic remains controversial. The major problem in determining the role of Nef in HIV/AIDS
has been the lack of tractable in vivo models where Nef’s complex pathogenic phenotype can be recapitulated.
Results: Intravenous inoculation (3000 to 600,000 TCIU) of BLT humanized mice with HIV-1LAI reproducibly establishes a
systemic infection. HIV-1LAI (LAI) replicates to high levels (peak viral load in blood 8,200,000 ± 1,800,000 copies of viral
RNA/ml, range 3,600,000 to 20,400,000; n = 9) and exhaustively depletes CD4+ T cells in blood and tissues. CD4+CD8+
thymocytes were also efficiently depleted but CD4+CD8- thymocytes were partially resistant to cell killing by LAI. Infection
with a nef-deleted LAI (LAINefdd) gave lower peak viral loads (1,220,000 ± 330,000, range 27,000 to 4,240,000; n = 17). For
fourteen of seventeen LAINefdd-infected mice, there was little to no loss of either CD4+ T cells or thymocytes. Both LAIand LAINefdd-infected mice had about 8% of total peripheral blood CD8+ T cells that were CD38+HLA-DR+ compared
<1% for uninfected mice. Three exceptional LAINefdd-infected mice that lost CD4+ T cells received 600,000 TCIU. All
three exhibited peak viral loads over 3,000,000 copies of LAINefdd RNA/ml. Over an extended time course, substantial
systemic CD4+ T cell loss was observed for the three mice, but there was no loss of CD4+CD8+ or CD4+CD8- thymocytes.
Conclusion: We conclude Nef is necessary for elevated viral replication and as a result indirectly contributes to CD4+ T
cell killing. Further, Nef was not necessary for the activation of peripheral blood CD8+ T cells following infection. However,
CD4+CD8+ thymocyte killing was dependent on Nef even in cases of elevated LAINefdd replication and T cell loss. This
depletion of thymic T cell precursors may be a significant factor in the elevated pathogenicity of CXCR4 trophic HIV-1.
Keywords: HIV-1, Nef, Humanized mouse, Replication, Pathogenicity

Background
HIV-1 infection leads to the near total loss of CD4+ T
cells and results in immune incompetence [1,2]. Nef is
considered to be a critical inducer of pathogenicity for
HIV-1, because there are several reported cases of
human infection by HIV-1 lacking a functional nef that
failed to develop AIDS for twelve years or more [3-9].
Also, support for an important role for simian immunodeficiency virus Nef in pathogenesis and disease progression comes from elegant experiments performed in non* Correspondence: Victor_Garcia@med.unc.edu
1
Division of Infectious Diseases, Center for AIDS Research, University of North
Carolina, Chapel Hill, NC 27599-7042, USA
2
Division of Infectious Diseases, UNC Center for AIDS Research, 2042 Genetic
Medicine, Campus Box 7042, Chapel Hill, NC 27599-7042, USA

human primates where the absence of Nef resulted in
delayed disease progression [10,11].
In vivo and ex vivo models of HIV-1 infection have been
utilized to assess the role of Nef in viral replication and
pathogenesis. Transgenic mouse models have demonstrated that Nef is the only HIV-1 protein that has direct
pathogenic effects in mice [12-14]. Results from an HIV-1
infection model employing ex vivo cultures of human tonsil suggested a role for Nef as a replication factor [15-18].
Ex vivo experiments with human fetal thymus organ culture (HF-TOC) found that nef functioned as a pathogenic
factor that does not enhance replication [19]. The findings
with HF-TOC were confirmed with the SCID-hu thy/liv
implant model in which infection can be extended beyond
the maximum two-week duration for most ex vivo models

© 2012 Zou et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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[19]. Other groups found a dual role for Nef in HIV-1 infection of SCID-hu thy/liv implants as a replication and a
pathogenesis factor [20,21]. Aldrovandi et al. found the
impact of nef-deleted HIV-1 on viral replication to be
dependent on the initial dose [22,23].
To address Nef’s role in HIV-1 pathogenesis during
prolonged systemic infection, we have investigated the
impact of inactivating nef on HIV-1 infection in vivo
using BLT humanized mice [24-27]. This advanced
model for human immune system reconstitution combines human stem cell engraftment in bone marrow with
a human fetal liver/thymus implant producing a full
range of systemically disseminated human immune cells
including B cells, monocytic cells, dendritic cells and T
cells. Human thymocyte education occurs within the
implanted thymus which is a fully human cellular compartment [24,26,28]. BLT humanized mice have both
human T cells and human thymocytes that can be
infected simultaneously. This distinction establishes the
BLT mouse model as a novel system for determining
in vivo pathogenesis attributable to HIV-1 accessory
genes. We inoculated mice with the strictly CXCR4tropic virus, HIV-1LAI (LAI), to maximize the pathogenic impact of the infection [29,30]. At three different
inoculums in BLT mice, LAI rapidly depletes human
CD4+ T cells in the peripheral blood and in tissues and
eliminates CD4+CD8+ thymocytes from the implanted
human thymic tissue [27].
At a low intravenous inoculum, we found nef-defective
LAI to be greatly delayed for replication with lower peak
viral loads relative to wild-type LAI. There was minimal
CD4+ T cell and CD4+CD8+ thymocyte killing. At a high
dose, the delay in nef-defective LAI replication was largely
lost and in a few exceptional cases there was gradual loss
of CD4+ T cells in blood and tissues. However, in no case
did nef-defective LAI infection result in loss of thymocytes.
With these findings we have established the humanized BLT mouse model as highly appropriate for directly studying the complex role of Nef in processes that
are critical for disease progression during HIV-1 infection. Our results suggest an indirect role for Nef in T
cell killing and a direct role for Nef in loss of thymic
function in HIV-1 infection [19,31,32].
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Results

intravenous doses chosen were 3000 TCIU, 30,000 TCIU
and 600,000 TCIU which correspond to 0.23 ng, 2.3 ng
and 45 ng of p24gag. We designated 3000 TCIU as a low
dose compared to inoculums of 12.5 and 25 ng of p24gag
directly injected into the thy/liv implant of SCID-hu
mice in previously published studies [22,23]. When BLT
mice were infected intravenously with a low dose of LAI
(3000 TCIU), all mice became systemically infected. The
virus replicated to a high level by two weeks and ultimately exceeded 106 copies of viral RNA/ml in peripheral
blood (Figure 1A). After the viral load reached about 106
copies of HIV RNA/ml, a decrease in peripheral blood
CD4+ T cells ensued (Figure 1B). CD4+ T cell depletion
proceeded such that CD4+ T cell levels were very low by
ten weeks. By contrast, naïve control mice had stable
CD4+ T cell levels in the peripheral blood for the entire
period of the experiment (Figure 1B). Increasing the infectious dose of virus by 10-fold (30,000 TCIU) gave an
acceleration of viral production with 106 copies of RNA/
ml appearing in blood by two weeks (Figure 1A). Concomitant with the earlier appearance of viral RNA, there
was a more rapid decline of CD4+ T cells (Figure 1B). Finally, a further 20-fold increase in viral inoculum (6X105
TCIU) gave massive viral replication, yielding 107 copies
of viral RNA/ml of blood (Figure 1A). There was also a
drastic loss of CD4+ T cells (Figure 1B) by 3 weeks.
These results demonstrate that intravenous infection of
BLT mice with LAI, at even the low dose, results in high
levels of virus in blood and severe depletion of peripheral blood CD4+ T cells. The observed CD4+ T cell depletion is consistent with the pathogenic nature of
CXCR4-trophic HIV infection in humans.
After establishing the effect of LAI infection on peripheral blood CD4+ T cell levels, we evaluated its effect on
CD4+ cell depletion in lymph nodes, spleen and in the
human thymic organoid (HTO). LAI depleted CD4+ T
cells from lymph node and spleen at all doses (Figure 1C).
The CD4+CD8+ double positive thymocytes were also efficiently depleted (Figure 1C). Interestingly, we noted that
CD4+CD8- single positive cells in the thymus were relatively resistant to depletion with only the highest inoculum
significantly decreasing the level of these cells (Figure 1C).
After evaluating the dose–response relationship of LAI
and establishing its pathogenic potential in BLT mice, we
next investigated the role of Nef.

Defining the course of infection in the BLT humanized
mouse with the highly pathogenic HIV-1LAI

Nef-defective LAI, LAINefdd

The goal of these experiments was to investigate the role
of Nef in the pathogenic sequela of HIV-1LAI (LAI)
in vivo. For this purpose we used the BLT humanized
mouse model that has been shown to recapitulate key
aspects of HIV infection in humans [27,33,34]. We first
investigated the relationship between the dose of viral
inoculum and the course/outcome of LAI infection. The

To follow the course of infection by LAI with an irreversibly inactivated nef (LAINefdd) in humanized BLT mice
LAINefdd was constructed (Figure 2). Two large deletions
flanking the polypurine tract were introduced into nef.
The double deletions reflect the long term convergent
evolution of nef-defective virus in patients to lose all nef
coding sequence except the PPT [5,7,35,36]. LAINefdd
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Figure 1 BLT humanized mice exhibited a profound loss of human CD4+ T cells/thymocytes following HIV-1LAI infection. (A-B) Three
cohorts of BLT humanized mice were exposed intravenously to increasing doses of HIV-1LAI (LAI). LAI inoculations included a low dose of 3000
TCIU (triangles), an intermediate dose of 30,000 TCIU (circles), and a high dose of 600,000 TCIU (diamonds). A fourth cohort consisted of naïve BLT
humanized mice that were not exposed to virus (squares). Longitudinal analysis of plasma viral load revealed efficient viral replication in each of
the three groups of LAI infected mice regardless of the inoculation dose, and no virus replication was observed in the naïve animals (A). In the
absence of infection in naïve BLT humanized mice, the percentage of human CD4+ T cells in the peripheral blood remains constant. In contrast,
LAI infected mice showed an inoculation dose dependent difference in the kinetics of CD4+ T cell loss. Asterisks represent the absence of
detectable levels of peripheral blood human CD4+ T cells in the BLT humanized mice infected with 600,000 TCIU of LAI at the time point
indicated (B). (C) Regardless of the inoculation dose, systemic loss of CD4+ T cells was observed in infected BLT humanized mice when compared
to naïve animals. Shown are the percentages of human CD4+ T cells present in peripheral blood, lymph nodes, and spleen, as well as the
percentages of CD4+CD8- and CD4+CD8+ thymocytes in the human thymic organoid. The percent of CD4+ T cells in peripheral blood or tissues
was relative to total CD3+ T cells while the percent of CD4+CD8- and CD4+CD8+ thymocytes was relative to total thymocytes. “—” indicates naïve
mice (n = 5 in PB, spleen and HTO or n = 4 in LN). Triangles indicate the increasing doses: 3000 TCIU (n = 3), 30,000 TCIU (n = 3), 600,000 TCIU
(n = 3). Unpaired two-tailed t tests were performed to compare the naïve mice to the mice in each LAI infection dose group within the same
tissue. If no difference was detected, the comparison is unmarked (alpha = 0.05). Comparisons yielding significant differences are represented by a
line connecting the arrows above the respective bars (*p < 0.05; **p < 0.01).

also models nef-defective virus from patients by maintaining conserved promoter elements in the 3′ end of U3
(Additional file 1: Figure S1). By a single round infection
assay with TZM-bl cells, LAINefdd exhibited the expected
reduction of virion infectivity [37,38]. The infectivity of
LAINefdd was not significantly different from that of LAINefXhoI with a non-deleted, frame-shifted nef (LAINefXhoI, see Additional file 2: Figure S2).
Infection of BLT mice with a low dose of LAINefdd

Four mice inoculated with 3000 TCIU of LAINefdd
(0.56 ng p24gag) became systemically infected. The

appearance of virus in peripheral blood was greatly
delayed from the 7–14 days seen for wild-type LAIinfected mice (Figure 3A, LAI-1,-2 and −3) to 30–55 days
for the four LAINefdd infected mice (p = 0.014, log rank
test). These results demonstrate a generally reduced level
of replication by the nef-deleted virus. However, in two
of four mice (LAINefdd-2 and LAINefdd-4) viral loads
did reach 106 copies of viral RNA/ml of plasma demonstrating the in vivo fitness of nef-defective virus
(Figure 3A). The other two mice (LAINefdd-1 and LAINefdd-3) had depressed viral replication with viral loads
clearly under 106 after sixty days. In contrast to the mice
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Figure 2 Schematic of WT LAI and LAINefdd. Three bars represent nef coding sequence and the U3 sequence for LAI, LAINefdd and patient
SG1 clone 27 sequence [35]. SG1 clone 27 reflects the tendency of patients with defective nefs to lose all remaining coding sequence [5,7,35,36].
The coding sequence of WT type LAI nef (NCBI Accession, K02013) is presented in the top bar (nucleotides 8390–9010). PPT, polypurine tract is
nucleotides 8662–8678. U3 consists of nucleotides 8678 to 9132. The core U3 promoter elements include two NF-κB binding sites, three SP1 sites
and the TFIID binding site or TATA box. In the lower bar the 5’ deletion incorporated into LAINefdd is 114 nucleotides (8495–8608). Within the
deletion, a four base insertion was added to create a frame shift (See Methods). The 3′ gap in LAINefdd is a frame-shifting deletion of 290 bases
(8692–8981). In the middle bar the deletions in SG1 isolate 27 are aligned with LAI. The gaps are not numbered for simplicity of presentation. The
5′ deletion in SG1 is 217 nucleotides and the 3′ deletion is 292 nucleotides.

infected with wild-type LAI, the LAINefdd infected mice
did not show significant depletion of their circulating
CD4+ T cells (Figure 3B). Even the two mice whose viral
loads reached 106 copies/ml maintained high levels of
CD4+ T cells in peripheral blood (Figure 3B). Therefore,
infection with a low dose of nef-deleted virus results in
delayed replication and most strikingly a minimal capacity to induce peripheral CD4+ T cell depletion.
To further explore the impact of nef-defective HIV infection, CD4+ T cells in lymphocyte containing tissues
were analyzed. As seen in Figure 3C, LAINefdd infection
did not result in depletion of CD4+ T cells in lymph
node (LN), spleen, bone marrow (BM), lung and liver
reflecting what was observed in peripheral blood
(Figure 3B and C). Consistent with the fact that at this
low dose wild-type LAI did not induce a severe depletion of CD4+CD8- thymocytes, infection with the LAINefdd also did not result in CD4+CD8- thymocyte
depletion (Compare Figure 1C and 3C). However, a dramatic difference between LAI and LAINefdd infections
was noted in the levels of CD4+CD8+ thymocytes
present in the implanted human thymus. Specifically, infection with wild-type virus resulted in a severe depletion of double positive thymocytes, but infection with
the nef-deleted virus did not deplete these cells
(Figure 3C). These data indicate that 3000 TCIU of LAINefdd is sufficient to establish an infection in BLT
humanized mice. However, consistent with Nef’s role as
an important replication and pathogenic factor LAINefdd was greatly reduced in its ability to initiate replication and to induce systemic CD4+ T cell and doublepositive thymocyte depletion.

Infection of BLT mice with an intermediate dose of
LAINefdd

We next increased the inoculum of nef-defective HIV by
10-fold (30,000 TCIU, 5.6 ng of p24gag) to assess the robustness of the nef-deleted phenotype. By two weeks,
two mice infected with the LAINefdd virus exhibited
delayed replication and relatively low levels of virus in
peripheral blood compared to LAI at the same dose
(Figure 4A, LAINefdd-5 and LAINefdd-7 versus LAI-4,
LAI-5, and LAI-6). These two LAINefdd-infected mice
exhibited similar replication kinetics to LAINefdd-1 and
LAINefdd-3 in Figure 3A. One mouse (LAINefdd-6) did
not show detectable viral replication in the blood for
8 weeks, but ultimately reached about 1.5 million copies
of viral RNA/ml (Figure 4A). A similar delay in viral replication has been reported for a humanized Rag2−/−γ−/−
c
mouse infected with YU-2 [39]. It should be noted that
despite active viral replication in these three mice receiving 30,000 LAINefdd TCIU, no CD4+ T cell decline was
observed in peripheral blood (Figure 4B). LAI at 30,000
TCIU gave a dramatic depletion of CD4+ T cells in blood
by seven weeks (Figures 4A and B).
We then examined the levels of systemic CD4+ T cell
depletion in the mice receiving this higher dose of virus.
In the mice injected with LAI there was a dramatic depletion of CD4+ T cells in the lymph node, spleen, bone
marrow, lung, liver and double positive thymocytes
(Figure 4C). Importantly, CD4+ T cells were preserved in
all the tissues analyzed from the mice infected with the
nef-defective virus including the human thymic organoid
(Figure 4C). These results demonstrate that, even with
10-fold higher inoculums, nef-deleted LAI is still highly
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Figure 3 Analysis of BLT humanized mice inoculated with a low dose of nef(−) or wild-type LAI. (A) Each line depicts longitudinal plasma
viral load data from individual BLT humanized mice infected with 3000 TCIU of LAINefdd (closed symbols) or LAI (open symbols). These data
demonstrate delayed replication of LAINefdd relative to LAI following low dose inoculation. (B) Each line depicts the percentage of CD4+ T cells
in peripheral blood over time where each animal’s symbol is matched to the mice in (A). Mice infected with a low dose of LAINefdd showed
minimal changes in CD4+ T cell percentages when compared to BLT humanized mice inoculated with an equal dose of LAI. (C) Naïve BLT
humanized mice (n = 5 in PB, spleen and HTO or n = 4 in LN, BM, lung and liver) and BLT humanized mice inoculated with 3000 TCIU of LAINefdd
(n = 4) exhibited similar levels of CD4+ cells while mice inoculated with the same dose of LAI (n = 3) exhibited a drastic reduction in these cells.
Shown are the percentages of human CD4+ T cells present in peripheral blood, lymph nodes, spleen, bone marrow, lung and liver, as well as the
percentages of CD4+CD8- and CD4+CD8+ thymocytes in the human thymic organoid. The percent of CD4+ T cells in peripheral blood or tissues
was relative to total CD3+ T cells while the percent of CD4+CD8- and CD4+CD8+ thymocytes was relative to total thymocytes. One-way ANOVA
with three Bonferroni multiple comparisons tests was performed to compare the results within each tissue. If no difference was detected, the
comparison is unmarked (alpha = 0.05). Comparisons yielding significant differences are represented by a line connecting the arrows above the
respective bars (**p < 0.01).

attenuated in its ability to deplete T cells and thymocytes. However, the delay in viral replication observed in
Figure 4A appeared to be less dramatic at this higher
dose for LAINefdd-5 and LAINefdd-7 than for LAINefdd infection at 3000 TCIU (Figure 3A). The extreme
delay in LAINefdd-6 will be considered in the
Discussion.
Infection of BLT mice with a high dose of LAINefdd

To further assess the phenotype of nef-defective virus
we tested the possibility that an additional 20-fold increase in viral inoculum would overwhelm the nefdeleted phenotype and result in pathogenic infection. A

total of ten BLT mice (LAINefdd-8 through LAINefdd17) were infected at this supraphysiological dose (6X105
TCIU, 112 ng of p24gag). Two different outcomes were
observed. With seven of these infections, there were at
most small drops in the levels of CD4+ T cells in peripheral blood; but with three mice substantial drops in CD4
+
T cells were observed (Figure 5B, 6B and 6D). As
shown in Figure 5A and B, inoculation of BLT mice with
6 × 105 TCIU of the wild-type LAI resulted in the rapid
appearance of high levels of virus in peripheral blood,
and depletion of peripheral blood CD4+. CD8+ T cells
were also depleted as seen in late stages of HIV-1 infection (not shown, [40,41]). Viral replication in two of the
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longitudinal plasma viral load data from individual BLT humanized mice infected with 30,000 TCIU of LAINefdd (closed symbols) or LAI (open
symbols). Two LAINefdd infected mice and all three LAI infected mice showed detectable viremia by three weeks post-exposure while one
LAINefdd infected mouse exhibited delayed detection of viremia. (B) Each line depicts the percentage of CD4+ T cells in peripheral blood over
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LAINefdd (n = 3) exhibited similar levels of CD4+ cells while mice inoculated with the same dose of LAI (n = 3) exhibited a drastic reduction in
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the comparison is unmarked (alpha = 0.05). Comparisons yielding significant differences are represented by a line connecting the arrows above
the respective bars (**p < 0.01).

LAINefdd mice yielded relatively high viral loads between 105 and 106 at two weeks (LAINefdd-9 and LAINefdd-11). In two other mice, plasma virus was less
than 100,000 at two weeks (LAINefdd-8 and LAINefdd10). At these levels of LAINefdd replication, CD4+ T cell
loss was essentially absent (Figure 5B).
At eight weeks post infection, we sacrificed the four
LAINefdd- and three LAI-infected mice to determine
the levels of CD4+ T cells in tissues (Figure 5C). Systemically, infection with wild type LAI at this high dose
resulted in near total depletion of CD4+ T cells in all tissues analyzed and double-positive thymocytes as well.

Interestingly, single positive CD4+ thymocytes did not
appear to be fully depleted by LAI (Figure 5C). Mice
infected with LAINefdd at this higher dose, maintained
normal levels of CD4+ T cells and double-positive thymocytes. These results demonstrate that over a 200-fold
range in the dose of virus, Nef is necessary for rapid loss
of CD4+ T cells and CD4+CD8+ thymocytes. A role for
Vpr, Env or possibly other HIV-1 proteins is not
excluded, but all of these genes are functional in LAI
and LAINefdd [42-44]. A recent report found no impact
of deleting vpu on CD4+ T cell depletion by HIV-1AD8+
in humanized mice [45].
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Figure 5 Analysis of BLT humanized mice inoculated with a high dose of nef(−) or wild-type LAI. (A) Each line depicts longitudinal plasma
viral load data from individual BLT humanized mice infected with 600,000 TCIU of LAINefdd (closed symbols) or LAI (open symbols). All LAINefdd
and LAI infected mice showed detectable viremia by two weeks post-exposure. (B) Each line depicts the percentage of CD4+ T cells in peripheral
blood over time where each animal’s symbol is matched to the mice in (A). Mice infected with a high dose of LAINefdd showed minimal
changes in CD4+ T cell percentages. In contrast, BLT humanized mice inoculated with an equal dose of LAI exhibited a very rapid decline of CD4
+
T cells. Asterisks indicate that essentially all of these cells are eventually depleted in BLT humanized mice infected with 600,000 TCIU of LAI. (C)
Naïve BLT mice (n = 5 in PB, spleen and HTO or n = 4 in LN) and BLT mice inoculated with 600,000 TCIU of LAINefdd (n = 4) exhibited similar
levels of CD4+ cells, while mice inoculated with the same dose of LAI (n = 3) exhibited a drastic reduction in these cells. Shown are the
percentages of human CD4+ T cells present in peripheral blood, lymph nodes and spleen, as well as the percentages of CD4+CD8- and CD4+CD8
+
thymocytes in the human thymic organoid. The percent of CD4+ T cells in peripheral blood or tissues was relative to total CD3+ T cells while
the percent of CD4+CD8- and CD4+CD8+ thymocytes was relative to total thymocytes. One-way ANOVA with three Bonferroni multiple
comparisons tests was performed to compare the results within each tissue. If no difference was detected, the comparison is unmarked
(alpha = 0.05). Comparisons yielding significant differences are represented by a line connecting the arrows above the respective bars (**p < 0.01).

Infection of BLT mice with a high dose of LAINefdd for an
extended time course

Our findings indicated that the dependence on Nef for
replication was clearly evident at low and intermediate
inoculums, but in some cases of the high initial inoculums of LAINefdd replication approached that of wildtype LAI. At high inoculum, the non-pathogenic phenotype of LAINefdd was still dramatic. We considered the
possibility that longer courses of sustained infection may
result in substantial CD4+ T cell depletion. For this purpose, we followed six LAINefdd-infected mice infected
with 6.0X105 TCIU for up to 170 days. As indicated
above, three mice exposed to this high dose of LAINefdd
exhibited reductions in CD4+ T cell levels in peripheral

blood. These three mice had uncharacteristically high
viral loads (>106 copies/ml of plasma) by two weeks
(Figure 6A). Associated with this high viral load was a
reduction of CD4+ T cells in the peripheral blood
(Figure 6B). However, despite viral loads near that of
wild-type virus, the time courses of CD4+ T cell depletion were significantly delayed for an average of ten
weeks for the nef-defective virus compared to less than
three weeks for LAI (Figure 5B and 6B, Mantel-Cox
Test, p = 0.025). The reduced levels of CD4+ T cells in
peripheral blood were mirrored by similar reductions in
the lymph node, spleen, lung and liver but not in bone
marrow of these animals (Figure 7, see bars designated
6AB). In contrast, the levels of thymocytes in these mice
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Figure 6 Distinct phenotypes in BLT humanized mice during long term infection with a high dose of LAINefdd. (A-B) Each line depicts
longitudinal plasma viral load data (A), or the CD4+ T cell percentages (B) from individual BLT humanized mice infected with 600,000 TCIU of
LAINefdd where each animal in (A) and (B) is symbol matched. Persistent viral replication and loss of CD4+ T cells in the peripheral blood were
observed in each of these mice. (C-D) Each line depicts longitudinal plasma viral load data (C) or the CD4+ T cell percentages (D) from individual
BLT humanized mice infected with 600,000 TCIU of LAINefdd where each animal in (C) and (D) is symbol matched. Viral replication and minimal
loss of CD4+ T cells in the blood were observed in these mice over this extended experimental analysis.

were not significantly reduced (Figure 7, CD4+CD8-,
CD4+CD8+, 6AB). The observations from these three
mice suggest that even in the case of clear reductions
CD4+ T cells, the nef-deleted virus was still much less
cytotoxic than the wild-type virus to thymocytes.
We considered the possibility that LAINefdd-12, LAINefdd-13 and LAINefdd-14 exhibited T cell depletion
because rearrangements of the remnants of nef coding
sequence may generate a severely truncated nef open
reading frame with some restoration of function. In
Additional file 3: Figure S3, we have aligned the
sequences for the nef regions obtained by RT-PCR from
the terminal bleed of these mice. All three of the
sequences are identical to the sequence of the input
virus. Therefore, nef from these three mice remained
non-functional.
In Figure 6C and D, we present the final three mice
that were infected with the highest dose of LAINefdd
and were followed for 5–6 months post infection. The
viral loads for these mice were maintained below 106
copies LAINefdd RNA/ml blood throughout the experiment (Figure 6C). For all of these mice, we observed

only small drops in peripheral blood CD4+ T cells
(Figure 6D). The results are in contrast to the complete
loss of CD4+ T cells observed as early as twenty-one
days in mice infected with 600,000 TCIU of LAI and further establish the significantly attenuated pathogenic
phenotype of LAINefdd. Consistent with the results in
Figure 6D for peripheral blood, the long term infections
also did not result in CD4+ T cell depletion in any of the
organs analyzed- lymph node, spleen, bone marrow,
lung, and liver (Figure 7, 6CD). Single and double positive thymocytes were also clearly resistant to depletion
by LAINefdd infection (Figure 7, 6CD). In summary, the
results indicate that the attenuated pathogenic phenotype of LAINefdd is not overwhelmed by a very high
dose of virus.
The relationship between viral load, T cell activation, and
the loss of peripheral blood CD4+ T cells and thymocytes

Recent studies of HIV-1 infection in BLT mice and
patients have found evidence of elevated CD38+HLA-DR
+
CD8+ T cells in blood [46,47]. We also observed this
effect with LAI infection. In naïve mice, 0.60% ± 0.11%,
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Figure 7 Impact of long-term infection with a high dose of LAINefdd in BLT humanized mice. The six BLT humanized mice infected with
600,000 TCIU of LAINefdd presented in Figure 6 were harvested for multiple tissue analyses at the last time points depicted in that figure. These
mice are referred to here by the panels in which they appear in that figure (6AB or 6CD). Data from these mice are presented alongside data
from naïve BLT humanized mice (n = 5 in PB, spleen and HTO or n = 4 in LN, BM, lung and liver) and BLT humanized mice inoculated with
600,000 TCIU of LAI (n = 3) to reveal that the CD4+ T cell loss patterns observed in the peripheral blood are mirrored by the multiple organ
analyses performed. Shown are the percentages of human CD4+ T cells present in peripheral blood, lymph nodes, spleen, bone marrow, lung
and liver, as well as the percentages of CD4+CD8- and CD4+CD8+ thymocytes in the human thymic organoid. Delta symbols serve to indicate no
data are available from bone marrow, lung or liver for LAI at 600,000 TCIU. The percent of CD4+ T cells in peripheral blood or tissues was relative
to total CD3+ T cells while the percent of CD4+CD8- and CD4+CD8+ thymocytes was relative to total thymocytes. One-way ANOVA with six
Bonferroni multiple comparisons tests was performed to compare the results within each tissue. If no difference was detected, the comparison is
unmarked (alpha = 0.05). Comparisons yielding significant differences are represented by a line connecting the arrows above the respective bars
(*p < 0.05; **p < 0.01).

(n = 5) of CD 8+ T cells in blood were CD38+HLA-DR+.
For LAI and LAINefdd infected mice, there were
8.5% ± 2.4% (n = 5) and 8.4% ± 2.6% (n = 3) CD38+HLADR+ CD8+ T cells in blood, respectively, which is significantly higher than for naïve mice (Mann Whitney test,
p = 0.012 and p = 0.036). LAI and LAINefdd infected
mice did not exhibit statistically different CD8+ T cell
activation (p = 0.96). One explanation of these results is
that relatively low levels of viral replication will induce T
cell activation, but not T cell killing. In Table 1, we
present the peak values for all twenty-six infected mice.
All nine mice infected with LAI had peak viral loads of
greater than 3X106 copies of LAI RNA in blood with a
mean ± S.E.M. of 8.2 × 106 ± 1.8 × 106 and a range of 3.6
to 20.4X106 copies of viral RNA/ml. Only three of
seventeen LAINefdd mice had peak viral loads >3X106
copies of viral RNA (LAINefdd-12, 13, and 14,
Figure 6A), and all three exhibited T cell loss
(Figure 6B). LAINefdd-2,-4,-6,-11 had peak viral loads of
1-2 × 106 ,but failed to deplete peripheral blood T cells
(Table 1, Figure 3A, 4A and 5A). Therefore, peak viral
loads >3,000,000 is associated with T cell depletion
(Table 1, T cell Depletion). CD4+CD8+ thymocyte depletion was not associated with peak viral load, but instead
was determined by the presence or absence of Nef expression (Table 1, CD4+CD8+ Depletion).
A combined mechanism of T cell killing brought about
by high viral replication plus reduced replacement of T
cells by the thymus may account for the dramatic loss of

T cells we have observed with LAI infection. In the case
of the three LAINefdd-infected mice that lost peripheral
blood T cells, there was no loss of CD4+CD8+ thymocytes which suggests that T cell replenishment may have
been ongoing (Figure 7). This could account for the
extended time course of T cell depletion for LAINefdd12, LAINefdd-13 and LAINefdd-14 relative to that
observed for LAI infections at the high viral dose
(Figures 5B and 6B).
HIV-1 infection results in depression of thymic output
of T cells [48]. We have determined that deletion of the
nef coding sequence prevents thymocyte loss by even a
high dose of nef-defective virus. For T cell depletion, the
cytoxcity of LAI appears to depend on reaching a
threshold of replication not usually achieved by LAINefdd. Our results are consistent with Nef indirectly depleting T cells by elevating HIV-1 replication. However,
CD4+CD8+ thymocytes appear to be depleted by a different mechanism in which Nef is acting as a pathogenic
factor.

Discussion
Recent reports have demonstrated the utility of the BLT
humanized mouse model for investigating HIV-1 infection [24,27,33,43,47]. HIV-1 establishes a systemic infection with high viral loads that exhibits pathogenic
properties by depleting human CD4+ T cells. Of particular interest to us was the extremely cytopathic phenotype of CXCR4-tropic viruses like HIV-1LAI. This well
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Table 1 Relationship between Peak Viral Load, T cell depletion and CD4+CD8+ Thymocyte Depletiona
Inoculum (TCIU)c

T cell Depletiond

CD4+CD8+ Depletione

7

600,000

Yes

Yes

LAI-8

7

1.19 × 10

600,000

Yes

Yes

LAI-9

1.13 × 107

600,000

Yes

Yes

LAI-4

6

6.70 × 10

30,000

Yes

Yes

LAI-2

5.63 × 106

3,000

Yes

Yes

LAI-6

6

4.99 × 10

30,000

Yes

Yes

LAI-3

4.64 × 106

3,000

Yes

Yes

LAI-1

6

4.25 × 10

3,000

Yes

Yes

LAINefdd-13

4.24 × 106

600,000

Yes

No

LAINefdd-12

6

3.77 × 10

600,000

Yes

No

LAI-5

3.59 × 106

30,000

Yes

Yes

LAINefdd-14

6

3.29 × 10

600,000

Yes

No

LAINefdd-11

2.07 × 106

600,000

No

No

LAINefdd-6

1.56 × 106

30,000

No

No

LAINefdd-4

1.25 × 106

3,000

No

No

LAINefdd-2

6

1.02 × 10

3,000

No

No

LAINefdd-17

9.93 × 105

600,000

No

No

LAINefdd-9

5

8.82 × 10

600,000

No

No

LAINefdd-16

4.90 × 105

600,000

No

No

LAINefdd-8

5

4.36 × 10

600,000

No

No

LAINefdd-15

3.00 × 105

600,000

No

No

LAINefdd-1

5

2.31 × 10

3,000

No

No

LAINefdd-3

2.20 × 105

3,000

No

No

LAINefdd-7

5

1.91 × 10

30,000

No

No

LAINefdd-10

7.73 × 104

600,000

No

No

30,000

No

No

Mouse
LAI-7

LAINefdd-5

Peak Viral Loadb (highest to lowest)
2.04 × 10

4

6.49 × 10

a

Summary of viral loads at peak viremia and depletion of T cell and double positive thymocytes.
b
Copies viral RNA/ml plasma. LAI, 8.15 × 106 ± 1.83 × 106 (n = 9); LAINefdd, 1.24 × 106 ± 0.32 × 106 (n = 17).
c
Dose of intravenous inoculum presented in tissue culture infectious doses (TCIU).
d
“Yes,” mice exhibiting reduction of peripheral blood CD4+ T cells below 50% of pre-infection level; viral load, 7.06 × 106 ± 1.47 × 106 (n = 12). “No,” mice exhibiting
peripheral blood CD4+ T cells not reduced below 50%; viral load, 0.70 × 106 ± 0.16 × 106 (n = 14).
e
“Yes,” CD4+CD8+ thymocytes reduced below 10% total thymocytes. Viral loads for “Yes” and “No” same as LAI and LAINefdd, respectively (b).

characterized and fully functional virus replicates to high
levels in BLT mice and rapidly depletes CD4+ T cells
from blood and tissues [27]. The dramatic nature of this
phenotype allowed us to investigate the role of Nef in
two decisive phenotypes for the development of AIDS:
maintenance of high levels of virus replication and depletion of CD4+ T cells and thymocytes [2,49]. Our studies show that at low inoculums the nef-deleted HIV-1LAI
was doubly defective with delayed replication and a severely blunted capacity to deplete CD4+ T cells and thymocytes. Mice infected with 3000 TCIU of wild-type
LAI exhibited a viral load of 105 copies/ml of RNA
14 days post inoculation, but LAINefdd-infected mice
only reached a viral load of 105 copies/ml at approximately 40, 40, 60, and 75 days post intravenous infection
(Figure 3A). In addition, the low dose LAI-infected mice

gave a 7-fold higher average peak viral load than the low
dose LAINefdd-infected mice (Table 1). The pathogenic
effect of Nef was also clearly demonstrated in Figure 3B,
as LAI infection (3000 TCIU) resulted in an almost
complete depletion of CD4+ T cells from peripheral
blood, but LAINefdd infection resulted in at best a modest reduction in CD4+ T cells levels even after viral loads
became elevated. Similar results were obtained at the
ten-fold higher dose of 30,000 TCIU of LAI and LAINefdd (Figure 4). Thus, Nef is important, not only for
efficient viral propagation, but also full pathogenicity
in vivo.
At 600,000 TCIU of LAINefdd, CD4+ T cells were not
depleted in seven of ten mice despite peak viral loads of
0.75 × 106 ± 0.25 × 106 demonstrating the great importance
of Nef for pathogenicity. However, three of ten mice
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infected with the highest dose of nef-deleted virus were
observed to have a pathogenic phenotype (Figure 5B).
These three mice exhibited efficient viral replication as
reflected by high peak viral loads (3.8 × 106 ± 0.2 × 106),
but delayed reductions in CD4+ T cell levels. We attribute
the loss of T cells in these mice to the high levels of replication of LAINefdd since no repair of the nef reading
frame was observed. Repair of the defective nef was not
expected, as all nef-defective HIV-1s from patients develop
expanded deletions to include most of the nef coding sequence while sparing the polypurine tract [4,7-9,36].
Precedent for a delayed pathogenic phenotype for nefdeleted HIV-1 has been reported for patients infected
with nef-deleted virus that were followed for over
15 years (Table 2). Three of eight patients lost CD4+ T
cells to the extent that anti-retroviral therapy became
necessary. The remaining five patients appear to be elite
controllers (Table 2). That 63% of patients infected with
nef-deleted HIV-1 that were documented for a sufficient
length of time are elite controllers is in stark contrast to
the less than 1% of elite controllers found in patients
infected with nef-intact HIV-1 [1]. A simple interpretation is that the patient’s immune system effectively controlled the nef-deleted HIV-1, but in three patients
where the nef-defective virus was able to maintain replication, CD4+ T cell levels began to decline after many
years [35,50]. Unfortunately, thymic function in these
three patients is not available.
Several Nef activities may be critical factors in the attenuation of LAI pathogenicity and replication that we
observed. For example, we observed considerable delay
Table 2 Outcomes for patients infected with HIV-1nef(−)
for longer than 15 yearsa
Patient Identifier

Viral Loadb

Date Infected

ARTc

D36

Low

1980

Yes, 1999

C54

Low

1984

No

C98

Low

1982

Yes, 1999

Patient 1

BLD

Prior to 1983

Yes, 1998

Patient SG1

BLD

1985

No

C49

BLD

1984

No

C64

BLD

1983

No

C135

BLD

1981

No

a

Patients reported to be infected by nef(−) HIV-1 for over fifteen years are
presented with the appropriate identifier. D36, C54, C98, C49, C64, and C135
are from the Sydney Blood Bank Cohort [5,50,51]. Patient 1 was reported by
Sullivan and co-workers [6,36,52]. Patient SG1 was reported by Benedetto and
co-workers [9,35]. bViral Load represented as “Low” indicates copies of viral
RNA were generally found to be less than 10,000 copies/ml of peripheral
blood but detectable. “BLD,” indicates viral load generally below the level of
detection. D36, C54 and C98 had viral loads that were consistently detectable
[50,51]. Patient 1, Patient SG1, C49, C64, and C135 viral loads were not
detectable [6,35,50]. The last four patients may have suppressed their HIV-1
infections by vigorous cytotoxic T cell responses [35,51]. C54 did not appear to
be progressing to AIDS at the time of death in 2001 [50]. cART is antiretroviral
therapy.

in appearance of viral RNA in the blood for the lowest
dose (Figure 3A). The loss of the enhancement of virion
infectivity function could be significant early in infection
to slow the rate of spread of the virus [37,38]. Subsequently, following the delay in replication, higher levels
of virus could reduce the impact of this effect and result
in some LAINefdd-infected mice presenting with viral
loads over 106. It is also important to determine the importance of another Nef activity, CD4 downregulation.
Previous results from infections of SCID-hu thy/liv
implants with Nefs mutated for residues (W57L58) critical for CD4 downregulation have given conflicting
results. As a result, the importance of CD4 downregulation for replication and pathogenicity in vivo is unresolved [21,22,53]. The results presented here demonstrate
that BLT mice have the potential to serve as an excellent
model to address the roles of specific Nef functions
described in vitro on Nef’s phenotype in vivo.
We did not observe loss of CD4+CD8+ thymocytes in
LAINefdd infections despite virtually complete depletion
of this same cell population by LAI. Further, it appeared
that CD4+CD8- thymocytes were resistant to killing by
LAI. This in vivo result is similar to the ex vivo result
reported by Choudhary et al. who reported a greater
cytotoxic effect by CXCR4-trophic HIV-1 on CD4+CD8+
than on CD4+CD8- thymocytes [31]. This effect was
attributed to CD4+CD8+, but not CD4+CD8- thymocytes, being primed for negative selection. Potentially
consistent with the proposed susceptibility of CD4+CD8
+
thymocytes to apoptosis, Nef has been reported to induce PD-1 and FasL [54,55].
In summary, we have demonstrated that LAI lacking
Nef function is greatly attenuated for pathogenicity.
However, under supraphysiological conditions of infection, this linkage is not absolute; and the defective virus
retains some capacity to systemically reduce CD4+ T
cells. HIV-1 gene products other than Nef that may be
responsible for the residual pathogenicity of LAINefdd
are Vpr or Env [42,43,56]. The availability of an in vivo
system to study the roles of HIV-1 accessory genes in
viral replication and depletion of CD4+ T cells and thymocytes will help address currently unresolved questions. In particular, the mechanism of Nef induced
killing of CD4+CD8+ thymocytes needs to be explored in
future studies as there is evidence of an important role
for HIV-1 inhibition of T cell replenishment from the
thymus in disease progression [32,57].

Conclusion
We have investigated the infection of BLT humanized
mice by wild-type and nef-defective HIV-1. With wild
type virus, there is rapid and near total depletion of CD4
+
T cells in blood and in multiple tissue compartments.
CD4+CD8+ thymocytes are also rapidly destroyed. With
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nef-defective virus, the course of infection is dramatically
different. Despite the establishment of robust viral replication, there is rarely much loss of CD4+ T cells over the
time frame that the wild-type virus systemically depletes
these cells. With a high initial inoculum and an extended
time course of infection, nef-defective virus may exhibit
pathogenic properties. These observations are consistent
with the conclusion that Nef is a replication factor and
indirectly accelerates T cell killing by inducing high
levels of viral replication. This mechanism does not
apply to CD4+CD8+ thymocytes, and our results suggest
that Nef has a direct role in thymocyte killing. The effectiveness of CXCR4-trophic HIV-1 in depleting CD4+
T cells may be enhanced by killing thymocytes and preventing thymic T cell replenishment.

Methods
Preparation of humanized BLT mice

Humanized BLT mice were prepared as previously
described
[24-27,34,58-60].
Briefly,
thymus/liver
implanted NOD/SCID or NOD/SCID IL-2γ−/− mice (The
Jackson Laboratories, Bar Harbor, ME) were transplanted
with autologous human CD34+ cells isolated from fetal
liver (Advanced Bioscience Resources, Alameda, CA).
Human reconstitution in the peripheral blood of these
mice was monitored periodically by flow cytometry
(FACSCanto; BD Biosciences). Mice were maintained either at the Animal Resources Center, UT Southwestern
Medical Center at Dallas (UTSWMC) or at the Division
of Laboratory Animal Medicine, University of North Carolina at Chapel Hill (UNC-CH) in accordance with protocols approved by the UTSWMC or UNC-CH Institutional
Animal Care and Use Committee. To ensure genetic diversity, seventeen different tissue donors were used to
generate three groups of mice used for the experiments
presented in this manuscript. Specifically, the percent engraftment for five naïve mice was 49.8% ± 13.9% human
CD45+ cells in blood from five of the donors, for the nine
LAI-infected mice it was 40.3% ± 8.0% human CD45+ cells
in blood from seven of the donors, and for seventeen LAINefdd-infected mice it was 51.4% ± 4.8% human CD45+
cells in blood from nine of the donors. Engraftment did
not significantly differ between the groups. Peak level of
virus in blood did not correlate with human cell
engraftment.

Cell lines and culture conditions

293T and TZM-bl cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM; Cellgro, Herndon, VA)
supplemented with 10% fetal bovine serum (FBS; Cellgro),
100 IU/ml of penicillin, 100 μg/ml streptomycin, and
2 mM glutamine (Cellgro) in 10% CO2 at 37°C.
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Proviral clones

The molecular clone, LAI (accession # K02013), is
described by Peden et al. [29]. pLAINefdd was made by
first removing the internal XhoI and Acc65I fragment
internal to nef, treating with Klenow and religating. This
removes nucleotides 8495–8608, inclusive. The deleted
LAI provirus was then cut at the reconstructed XhoI
site, treated with Klenow and religated to introduce a
frame shift (four base insertion) in addition to the deletion 114 bases. Second, nucleotides, 8692–8981, inclusive, were deleted by a site-directed mutagenesis strategy
(Stratagene, USA). LAINefXhoI was constructed to be
defective for nef by cutting the provirus with the single
cutter XhoI, filling in with Klenow and religating. This
leaves nef coding sequence intact but introduces a fourbase frameshift at nef codon 35. Lack of Nef expression
by the mutants was confirmed by Western blot analysis.
Our LAI construct is comparable to the double deleted
NL4-3 construct of Gibbs et al. [61]. Converting NL4-3
numbers to homologous LAI numbers to compare the
two constructs: the deletions were NL4-3/LAI (8428/
8495 to 8650/8608 for the 5′ deletion and 8718/8692 to
8983/8981 for the 3′ deletion). This NL4-3 construct
was used to produce virus for SCID-hu studies [22].
Virus production, exposure of BLT mice to HIV-1LAI or nefdeleted HIV-1LAI, tissue harvesting and cytometric
analyses

Stocks of LAI, LAINefdd and LAIXhoI were prepared and
titered as we previously described [62,63]. Briefly, proviral
clones were transfected into 293T cells. Viral supernatant
was collected 48 hours after transfection and diluted in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 100 IU penicillin/ml,
100 μg/ml streptomycin, and 2 mM glutamine. TZM-bl
cells were infected in 12-well tissue culture plates with
0.4 ml of virus containing medium for two hours. Then
1.0 ml of supplemented DMEM was added, and the plates
were incubated overnight. Virus containing medium was
removed the next day and the incubation was continued
for 24 hours. The cells were fixed and stained (40 hours
after first exposure to virus). The titers of these viral stocks
were determined in triplicate and at least two different
titer determinations were performed in each batch of virus
used for all the experiments described in this manuscript.
p24gag was determined for each prep of virus by ELISA.
Intravenous exposure of BLT mice with HIV-1LAI or
HIV-1LAIdd was conducted via tail vein injection with
3000, 30,000 and 6 × 105 tissue culture infectious units
(TCIU). Viral load in peripheral blood of infected mice
was monitored longitudinally by quantitative real-time
PCR using Taqman RNA to-C™T 1-step kit from Applied
Biosystems, USA [34,64]. The sequences of the forward
and reverse primers and the Taqman probe for PCR
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were: 5′- CATGTTTTCAGCATTATCAGAAGGA- 3′,
5′-TGCTTGATGTCCCCCCACT- 3′, and 5′- FAM
CCACCCCACAAGATTTAAACACCATGCTAA- Q- 3′
, respectively. CD4+ and CD8+ T cell levels were monitored by flow cytometric analysis.
Flow cytometric immunophenotyping was performed
on peripheral blood samples longitudinally and mononuclear cells were isolated from tissues at harvest. Whole
peripheral blood from humanized mice was analyzed
according to the BD Biosciences Lyse/Wash protocol
(Cat. No. 349202) as we have previously described
[24,26,27]. Briefly, following antibody labeling of whole
blood, red blood cells were lysed. The remaining cells
were washed, fixed; and the sample was analyzed by flow
cytometry. Tissue mononuclear cell isolations and immunophenotyping analyses were also performed according to
published methods [24,26,27]. Flow cytometric gating for
all samples was performed as follows: (step 1) forward and
side scatter properities were utilized to set a live cell gate;
(step2) live cells were then analyzed for expression of the
human pan-leukocyte marker CD45; (step 3) human leukocytes were then analyzed for hCD3, hCD4 and/or hCD8
expression (step 4) in the case of CD8+ T cell activation
analyses, peripheral blood human CD8+ T cells were analyzed for hCD38 and HLA-DR expression.
Sequence analysis of plasma virions

Viral RNA was extracted from 20 μl of plasma from
infected mice using the QIAamp Viral RNA Mini kit
(Qiagen Sciences, USA). RNA was then reverse transcribed into cDNA, which was then subject to nested
PCR. The outer primers for nef amplification are: 5′AGCTTGCTCAATGCCACAGCC-3′
and
5′GCTGCATATAAGCAGCTGCTTTTTG-3′. And the
inner primers are: 5′-TAGAGCTATTCGCCACATACC3′ and 5′-GCTTGCTACAAGGGACTTTCCGC-3′. Gel
purified PCR products were sequenced and the
sequences aligned to HIVLAI sequences to determine if
sequence changes had occurred.
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is numbered from the transcription start site to the 5′ end of U3 (−1 to
−454). R (brown) is numbered from +1 to +97 and U5 (orange) is
numbered from +98 to +181. Above LAI LTR sequence is the translation
of nef in three-letter amino acid code (black). The three colors for LAI U3
nucleotide sequence indicate- U3 general sequence (black), U3 sequence
that is deleted in LAINefdd (red) and U3 sequence that represents
transcription factor binding sites (green). D36 LTR is a nucleotide
sequence from the donor in the Sydney Blood Bank Cohort (NCBI
Accession DQ287276). The sequence is derived from a blood sample
taken approximately 20 years post infection and is representative of nefs
with large deletions on either side of the PPT [4,5]. D36 U3 sequence is
presented in black and green. Black is general U3 sequence and green
represents transcription factor binding sites. Dashes (black) represent D36
deleted sequence. Blue “X’s” are for reported upstream transcription
factor binding sites that are deleted in D36 LTR sequence. Asterisks
indicate identical residues between LAI and D36 LTRs. A four base
insertion in D36 LTR between A(−95) and C(−94) is shown below the
asterisks. D36 R and D36 U5 are brown and orange, respectively. The
sequence for D36 U5 is not complete. The conserved U3 core promoter
(−1 to −122) contains binding sites for multiple transcription factors.
Estable et al. [65] determined that the conservation of the individual
binding sites to be- TFIID (97%), three intact SP1 (95%) and two intact
NF-κB (85%). Just upstream of the core promoter the Ras response
element binding factor 2, RBF-2 (63%) and E26 transformation-specific
domain protein, Ets (87%) also are conserved. Note that all of these sites
(green) are intact in LAINefdd and are present in the D36 LTR with the
exception of Ets and possibly RBF-2. Binding sites for upstream
stimulatory factor (USF), nuclear factor of activated T cells (NFAT) and
chicken ovalbumin upstream promoter transcription factor (COUP-TF) are
deleted in LAINefdd and D36 (blue). Deletion of the USF palindromic
binding site, CACGTG, was reported to enhance viral replication [66].
However, CACGTG is only 15% conserved and USF1 and USF2
overexpression activates HIV LTR independently of this site [65,67]. NFAT1 binding was reported to negatively impact HIV-1 replication though
later studies found no effect and demonstrated that NFAT-1 binds to the
tandem NF-κB sites [66,68,69]. COUP-TF binds at the gapped palindrome
GGTCAN9TGACC (LAI LTR nucleotides −348 to −320). This palindrome is
found in LAI but is not conserved in subtype B nefs [70,71].
Additional file 2 Figure S2. Infectivity of LAINefXhoI and LAINefdd
are similar. A single round infection assay was performed with the
indicator cell line, TZM-bl, with LAI, LAINefXhoI or LAINefdd. The mean
infectivity of LAI (10,200 ± 1270 TCIU per ng p24gag) was set at 100%. The
infectivities of LAINefXhoI (5260 ± 630 TCIU per ng p24gag) and LAINefdd
(3400 ± 570 per ng of p24gag) were significantly less than LAI but not
different from each other. Comparisons yielding significant differences
are represented by a line connecting the arrows above the respective
bars (**p < 0.01).
Additional file 3 Figure S3. Alignment of nef sequences with LAI
and LAINefdd sequences. nef was amplified by RT-PCR from blood of
LAINefdd-12, LAINefdd-13 and LAINefdd-14 collected at tissue harvest (40,
78 and 90 days, respectively; Figure 6A and 6B). The amplified products
were sequenced and aligned by Clustal X. Asterisks on the bottom line
represent identical residues and dashes represent nucleotides deleted
during the construction of the proviral clone of LAINefdd.

Statistics

Log-rank (Mantel-Cox) tests (alpha level, 0.05) for initial
viremia detection were performed using survival analyses
in Prism version 4 (GraphPad). Unpaired two-tailed t tests
and one-way ANOVA were also performed in Prism version 4 (Graph Pad). All data were plotted as mean ± S.E.M.

Additional files
Additional file 1 Figure S1. Alignment of LTR sequence from HIV-1
LAI and Sydney Blood Bank Cohort Patient D36. LAI LTR is the
nucleotide sequence of LAI U3, R and U5. U3 (black, red and green) and
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